In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.
Study Explores Palindromic Rheumatism to Predict RA Development
Research from Ellingwood et al. examines how often patients diagnosed with early RA experience episodic joint inflammation and describes characteristics that may result in RA development.
Diet, Microbes & Inflammation: Unique Microbial Genetic Strains in Inflammatory Disease, Plus a Possible Arthritis Diet
Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.
Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients
(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests. Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target…
Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease
COVID-19-related deaths are significantly higher in communities with higher proportions of Black, Latinx, Asian American or other racial/ethnic minorities.
CDC-Funded RISE Project Aims to Improve Systemic Lupus Erythematosus Patient Outcomes
In September 2020, the ACR received a $7 million grant for a four-pronged SLE approach that seeks to address gaps and inequities in SLE through physician education, medical school outreach, pediatric support and disease management.
Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis
Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.
The Effects of IL-17A Inhibitors on the Microbiota
The use of an interleukin (IL) 17A inhibitor resulted in gut microbial dysbiosis and features of subclinical intestinal inflammation in a subgroup of psoriatic arthritis (PsA) and spondyloarthritis (SpA) patients, according to a multidisciplinary, collaborative study across several institutions published in Arthritis & Rheumatology.1 Understanding the downstream effects of these perturbations is an important step…
Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients
In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…
Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap
Drug-induced lupus erythematosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 342
- Next Page »